These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36434007)

  • 21. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
    Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
    Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Genetic or Cellular Impairments in Type I IFN Immunity in a Cohort of Young Adults with Critical COVID-19.
    Covill LE; Sendel A; Campbell TM; Piiroinen I; Enoksson SL; Borgström EW; Hansen S; Ma K; Marits P; Norlin AC; Smith CIE; Kåhlin J; Eriksson LI; Bergman P; Bryceson YT
    J Clin Immunol; 2024 Jan; 44(2):50. PubMed ID: 38231281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
    Quarleri J; Delpino MV
    Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
    Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
    J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia.
    Bastard P; Zhang Q; Cobat A; Jouanguy E; Zhang SY; Abel L; Casanova JL
    C R Biol; 2021 Jun; 344(1):19-25. PubMed ID: 34213846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examination of autoantibodies to type I interferon in patients suffering from long COVID.
    Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH
    J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
    Abers MS; Rosen LB; Delmonte OM; Shaw E; Bastard P; Imberti L; Quaresima V; Biondi A; Bonfanti P; Castagnoli R; Casanova JL; Su HC; Notarangelo LD; Holland SM; Lionakis MS
    Immunol Cell Biol; 2021 Oct; 99(9):917-921. PubMed ID: 34309902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Anti-Interferon-Alpha Autoantibody Levels in Severe/Critical COVID-19 Patients from Peru.
    Pons MJ; Mayanga-Herrera A; Palomino-Kobayashi LA; Quispe AM; Ugarte-Gil MF
    J Interferon Cytokine Res; 2023 Dec; 43(12):565-570. PubMed ID: 37906115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses.
    Chen Y; Song W; Li C; Wang J; Liu F; Ye Z; Ren P; Tong Y; Li J; Ou Z; Lee AC; Cai JP; Wong BH; Chan JF; Yuen KY; Zhang AJ; Chu H
    EBioMedicine; 2023 Mar; 89():104485. PubMed ID: 36857860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.
    Li C; Luo F; Liu C; Xiong N; Xu Z; Zhang W; Yang M; Wang Y; Liu D; Yu C; Zeng J; Zhang L; Li D; Liu Y; Feng M; Liu R; Mei J; Deng S; Zeng Z; He Y; Liu H; Shi Z; Duan M; Kang D; Liao J; Li W; Liu L
    Ann Med; 2021 Dec; 53(1):391-401. PubMed ID: 33620016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients.
    Contoli M; Papi A; Tomassetti L; Rizzo P; Vieceli Dalla Sega F; Fortini F; Torsani F; Morandi L; Ronzoni L; Zucchetti O; Pavasini R; Fogagnolo A; Volta CA; Bartlett NW; Johnston SL; Spadaro S; Campo G
    Front Immunol; 2021; 12():648004. PubMed ID: 33767713
    [No Abstract]   [Full Text] [Related]  

  • 35. Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome.
    Masood KI; Yameen M; Ashraf J; Shahid S; Mahmood SF; Nasir A; Nasir N; Jamil B; Ghanchi NK; Khanum I; Razzak SA; Kanji A; Hussain R; E Rottenberg M; Hasan Z
    Sci Rep; 2021 Nov; 11(1):22958. PubMed ID: 34824360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19.
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934766. PubMed ID: 34538868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.